uniQure N.V. Increase (Decrease) in Deferred Revenue
uniQure N.V. (QURE) reported Increase (Decrease) in Deferred Revenue of -$21.08 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-14
- uniQure N.V. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$1.46M.
- uniQure N.V. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$16.30M.
- uniQure N.V. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$2.05M.
- uniQure N.V. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$1.27M.
- uniQure N.V. increase (decrease) in deferred revenue for fiscal 2017 was -$21.08M.
- uniQure N.V. increase (decrease) in deferred revenue for fiscal 2016 was -$5.70M, a 109.02% decline from fiscal 2015.
- uniQure N.V. increase (decrease) in deferred revenue for fiscal 2015 was $63.17M.
- uniQure N.V. increase (decrease) in deferred revenue for fiscal 2014 was -$421.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$17.76M derived: sum of 2 quarters · filed 2018-03-14 | -$19.81M derived: sum of 3 quarters · filed 2018-03-14 | -$21.08M 10-K · filed 2018-03-14 |
| 2017-09-30 | -$16.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$18.35M derived: sum of 2 quarters · filed 2017-11-01 | -$19.62M 10-Q · filed 2017-11-01 | -$20.67M derived: sum of 4 quarters · filed 2018-03-14 |
| 2017-06-30 | -$2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$3.31M 10-Q · filed 2017-08-08 | -$4.36M derived: sum of 3 quarters · filed 2018-03-14 | -$6.12M derived: sum of 4 quarters · filed 2018-03-14 |
| 2017-03-31 | -$1.27M 10-Q · filed 2017-05-09 | -$2.31M derived: sum of 2 quarters · filed 2018-03-14 | -$4.08M derived: sum of 3 quarters · filed 2018-03-14 | -$5.55M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$2.81M derived: sum of 2 quarters · filed 2018-03-14 | -$4.28M derived: sum of 3 quarters · filed 2018-03-14 | -$5.70M 10-K · filed 2018-03-14 |
| 2016-09-30 | -$1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$3.23M derived: sum of 2 quarters · filed 2017-11-01 | -$4.65M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$2.89M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | -$1.42M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $63.17M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | -$421.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |